Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis A

Yeon Seok Seo, Kwang Gyun Lee, Eun Suk Jung, Hyonggin An, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun, Hyung Joon Yim, Hong Sik Lee, Soon-Ho Um, Chang Duck Kim, Ho Sang Ryu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6%) were men. ANAs were detected in 179 AHA patients (42.4%). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7% during the prodromal period vs 52.1% during the icteric or recovery period, p<0.001) and sex (56.2% in women vs 33.8% in men, p>0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.

Original languageEnglish
Pages (from-to)340-347
Number of pages8
JournalGut and Liver
Volume5
Issue number3
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Hepatitis A
Antinuclear Antibodies
Alanine Transaminase
Hospitalization
Prodromal Symptoms
International Normalized Ratio
Acute Liver Failure
Incidence
Indirect Fluorescent Antibody Technique
Bilirubin

Keywords

  • Autoimmune
  • Clinical outcome
  • Complication
  • Hepatitis A

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis A. / Seo, Yeon Seok; Lee, Kwang Gyun; Jung, Eun Suk; An, Hyonggin; Kim, Ji Hoon; Yeon, Jong Eun; Byun, Kwan Soo; Yim, Hyung Joon; Lee, Hong Sik; Um, Soon-Ho; Kim, Chang Duck; Ryu, Ho Sang.

In: Gut and Liver, Vol. 5, No. 3, 01.09.2011, p. 340-347.

Research output: Contribution to journalArticle

@article{54498940005d4c09af0f5e392e35ad23,
title = "Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis A",
abstract = "Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6{\%}) were men. ANAs were detected in 179 AHA patients (42.4{\%}). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7{\%} during the prodromal period vs 52.1{\%} during the icteric or recovery period, p<0.001) and sex (56.2{\%} in women vs 33.8{\%} in men, p>0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.",
keywords = "Autoimmune, Clinical outcome, Complication, Hepatitis A",
author = "Seo, {Yeon Seok} and Lee, {Kwang Gyun} and Jung, {Eun Suk} and Hyonggin An and Kim, {Ji Hoon} and Yeon, {Jong Eun} and Byun, {Kwan Soo} and Yim, {Hyung Joon} and Lee, {Hong Sik} and Soon-Ho Um and Kim, {Chang Duck} and Ryu, {Ho Sang}",
year = "2011",
month = "9",
day = "1",
doi = "10.5009/gnl.2011.5.3.340",
language = "English",
volume = "5",
pages = "340--347",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "3",

}

TY - JOUR

T1 - Clinical significance of the detection of antinuclear antibodies in patients with acute hepatitis A

AU - Seo, Yeon Seok

AU - Lee, Kwang Gyun

AU - Jung, Eun Suk

AU - An, Hyonggin

AU - Kim, Ji Hoon

AU - Yeon, Jong Eun

AU - Byun, Kwan Soo

AU - Yim, Hyung Joon

AU - Lee, Hong Sik

AU - Um, Soon-Ho

AU - Kim, Chang Duck

AU - Ryu, Ho Sang

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6%) were men. ANAs were detected in 179 AHA patients (42.4%). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7% during the prodromal period vs 52.1% during the icteric or recovery period, p<0.001) and sex (56.2% in women vs 33.8% in men, p>0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.

AB - Background/Aims: The findings of several recent studies suggest that antinuclear antibodies (ANAs) are frequently detected in patients with acute hepatitis A (AHA). However, the clinical significance of a positive ANA test remains uncertain. This study was performed to evaluate the clinical significance of ANAs in AHA patients. Methods: All patients admitted with AHA were consecutively enrolled in this study. An ANA assay was performed by indirect immunofluorescence during hospitalization. ANA positivity was defined as an ANA titer ≥1:80. The peak international normalized ratio (INR), peak alanine aminotransferase (ALT) and peak bilirubin levels were assessed over the duration of the hospitalization, and the incidence of AHA complications was evaluated. Results: A total of 422 patients were enrolled in this study (age, 31±7 years), of which 260 (61.6%) were men. ANAs were detected in 179 AHA patients (42.4%). The proportion of ANA-positive patients varied significantly with AHA status on the day of the ANA assay (4.7% during the prodromal period vs 52.1% during the icteric or recovery period, p<0.001) and sex (56.2% in women vs 33.8% in men, p>0.001). The ANAs became undetectable in all ANA-positive patients within 3 months. The incidence of complications, including mortality, fulminant hepatic failure, renal dysfunction, relapse, and cholestatic hepatitis, did not differ significantly between ANA-positive and ANA-negative patients. Conclusions: ANAs were detected frequently and transiently in patients with AHA, especially after their peak-ALT day. The presence of ANAs may not be associated with the clinical outcome of AHA, but simply with AHA status on the ANA assay day.

KW - Autoimmune

KW - Clinical outcome

KW - Complication

KW - Hepatitis A

UR - http://www.scopus.com/inward/record.url?scp=80052474791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052474791&partnerID=8YFLogxK

U2 - 10.5009/gnl.2011.5.3.340

DO - 10.5009/gnl.2011.5.3.340

M3 - Article

C2 - 21927664

AN - SCOPUS:80052474791

VL - 5

SP - 340

EP - 347

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 3

ER -